Provided herein are anti-HIV Env antibodies and their use in the treatment or prevention of HIV/AIDS.

Provided are methods for identifying patient populations infected with HIV that can be targeted by antibodies that bind to HIV gp120 CD4 binding site (CD4bs) region.

Methods of treatment for HIV employing T cells expressing both a chimeric antigen receptors targeted to HIV and a CMV-specific T cell receptor.

The present invention relates to the field of virology. More specifically, the present invention provides compositions and methods useful for elimination of human immunodeficiency virus-1 (HIV-1) reservoir cells. In several embodiments, the single chain diabody binds human immunodeficiency virus 1 Envelope protein variable loops 1 and 2 (HIV-1 Env V1/V2) and human type III Fc receptor (CD16). In a specific embodiment, the scDb comprises (a) an anti-HIV-1 Env V1/V2 antigen binding fragment comprising a VH comprising or consisting of SEQ ID NO:1; (b) an anti-HIV Env V1/V2 antigen binding fragment comprising a VL comprising or consisting of SEQ ID NO:5; (c) an anti-CD16 antigen binding fragment comprising a VH comprising or consisting of SEQ ID NO:17; and (d) an anti-CD16 antigen binding fragment comprising a VL comprising or consisting of SEQ ID NO:21.

The present invention discloses immunogenic compositions including recombinant peptides and proteins comprising human immunodeficiency viruses (HIV) antigens and immunogens, e.g., gp 120 protein peptides. In some aspects, the immunogenic composition comprises a secreted fusion protein comprising a soluble HIV viral antigen joined by in-frame fusion to a C-terminal portion of a collagen which is capable of self-trimerization to form a disulfide bond-linked trimeric fusion protein. In some aspects, the immunogenic compositions provided herein are useful for generating an immune response, e.g., for treating or preventing an HIV infection. In some aspects, the immunogenic compositions provided herein may be used in a vaccine composition, e.g., as part of a prophylactic and/or therapeutic vaccine. Also provided herein are methods for producing the recombinant peptides and proteins, prophylactic, therapeutic, and/or diagnostic methods, and related kits.

The present invention relates to bispecific antigen-binding polypeptides that may be used to remove unwanted agents, such as viruses or toxins, from the body and target them for degradation. The bispecific antigen-binding polypeptides of the invention have a first antigen-binding domain that binds an extracellular molecule and a second antigen-binding domain that binds to a cell surface protein, whereby the cell surface protein mediates internalisation of the bound complex. The invention also relates to pharmaceutical compositions comprising the bispecific antigen-binding poly peptides, and to methods of targeting an extracellular molecule for cellular internalisation and degradation via the lysosomal pathway.

Antibodies and antigen binding fragments that specifically bind to gp120 and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.

The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.

The present invention provides bispecific antigen-binding molecules having a monovalent arm specific to a first target antigen (e.g., a T cell antigen, such as CD3) and a bivalent arm specific for a second target antigen (e.g., a tumor antigen, such as HER2). Bispecific antigen-binding molecules are useful in the treatment of disorders, such as cancer (e.g., HER2-positive cancer). The invention also features methods of producing bispecific antigen-binding molecules, methods of treating disorders using bispecific antigen-binding molecules, and compositions including bispecific antigen-binding molecules.

Antigen binding proteins of the invention bind to Human Immunodeficiency Virus (HIV) envelope protein and are useful in treating and preventing HIV infection. In particular, the antigen binding proteins bind to two different epitopes on HIV envelope surface glycoprotein 120 (gp120): the V3 loop region and the CD4 binding site.